Introduction to Circulating RNA-Based Cancer Diagnostics
Cancer diagnostics have improved significantly over the past decades, yet there is still a strong demand for simple, minimally invasive, and cost-effective diagnostic approaches. Blood-based molecular diagnostics have become an important area of research because they offer the possibility of detecting cancer through a routine blood sample instead of invasive tissue biopsies.
Early studies mainly focused on detecting circulating tumor cells (CTCs) in the bloodstream. Although tumor cells can often be identified in patients with advanced malignancies, the sensitivity of these methods for early-stage cancer detection and recurrence monitoring has remained limited. As a result, researchers began exploring alternative biomarkers, including extracellular nucleic acids such as DNA and RNA.
The discovery of circulating tumor-derived DNA in plasma and serum opened a new direction in molecular oncology. Several investigations demonstrated that cancer-associated genetic alterations present in tumor tissues could also be detected in circulating DNA from patient blood samples. These findings showed promising specificity for cancer diagnosis. However, DNA-based approaches still face several limitations, including low mutation frequency, technical complexity, and insufficient sensitivity for broad clinical implementation.
Another promising biomarker is circulating extracellular RNA. For many years, scientists believed that RNA could not survive in blood because plasma contains high concentrations of ribonucleases (RNases), enzymes that rapidly degrade RNA molecules. More recent investigations, however, demonstrated that extracellular RNA can remain stable in plasma and serum despite the presence of these degradative enzymes.
Researchers subsequently showed that tumor-associated messenger RNAs (mRNAs) could be amplified from blood samples using reverse transcription polymerase chain reaction (RT-PCR). Tumor-related transcripts linked to melanoma, breast cancer, and other malignancies were successfully detected in patient serum samples. Despite these advances, diagnostic sensitivity remained relatively low, typically ranging from 25% to 78%, which was insufficient for reliable clinical application.
Several factors contributed to these limitations:
- Poor understanding of the biological nature of circulating RNA
- Inefficient RNA extraction methods
- Degradation of RNA during processing
- Use of very small plasma or serum volumes
- Limited knowledge of RNA protection mechanisms in blood
To address these challenges, this study investigated the biological characteristics of circulating RNA, mechanisms responsible for RNA stability in plasma, and optimization strategies for RNA extraction and amplification for cancer diagnostics.
Biological Nature of Circulating Extracellular RNA
Stability of RNA in Blood Plasma
One of the most important findings was that endogenous circulating RNA remained stable in plasma for several hours at room temperature, even though externally added RNA was immediately degraded by plasma RNases. This observation confirmed that naturally occurring plasma RNA is protected by specific biological mechanisms.
Researchers tested several hypotheses to explain RNA stability in circulation.
RNA–DNA Hybrid Hypothesis
One proposed mechanism suggested that circulating RNA forms hybrids with DNA molecules. Such RNA–DNA complexes could theoretically resist degradation by RNases and DNases.
To evaluate this theory, plasma samples were treated with:
- RNase-H
- DNase
- RNase A/T1
The experiments demonstrated that none of these enzymes significantly reduced circulating RNA levels. These results indicated that RNA–DNA hybrid formation was unlikely to be the primary protective mechanism.
Vesicle-Mediated RNA Protection
An alternative explanation proposed that extracellular RNA is enclosed within lipid vesicles, lipoprotein complexes, or apoptotic bodies.
Several experimental observations strongly supported this hypothesis:
- Plasma RNA remained stable under normal conditions
- Addition of detergents such as SDS and Triton-X destroyed detectable RNA
- RNA concentration decreased dramatically after filtration through 0.2 µm membranes
- RNA-containing vesicles could be isolated from plasma and serum
These findings suggest that circulating RNA is protected inside membrane-associated structures that shield RNA molecules from RNase activity.
Possible biological sources of these vesicles include:
- Apoptotic tumor cells
- Platelet-derived vesicles
- Actively secreted exosomes
- Lipoprotein complexes
This mechanism explains how RNA can survive in the highly degradative environment of blood plasma.
Study Design and Sample Collection
Patient Cohorts
The investigation included several patient groups:
Esophageal Cancer Group
Plasma samples were collected from patients diagnosed with esophageal cancer. Additional samples were obtained from individuals with gastroesophageal reflux disease (GERD) and healthy volunteers to serve as controls.
Melanoma Group
Serum samples were collected from patients with advanced melanoma and compared with samples from healthy individuals and GERD patients.
All blood samples were collected using standardized protocols approved by institutional review boards.
Plasma and Serum Processing
Blood samples underwent centrifugation to separate plasma or serum from cellular components.
Two processing strategies were evaluated:
- Single centrifugation
- Double centrifugation
The second centrifugation step was designed to eliminate residual cells and platelets. However, researchers observed that this additional centrifugation dramatically reduced RNA yield, suggesting that important RNA-containing particles may have been removed during processing.
The pellet obtained after the second centrifugation contained:
- Platelets
- Microparticles
- Possible apoptotic vesicles
These findings indicated that a substantial portion of circulating RNA may be associated with particulate structures rather than existing as free RNA molecules.
Optimization of RNA Isolation Protocols
Comparison of RNA Extraction Methods
Nine different RNA extraction protocols were evaluated to determine their efficiency for isolating plasma RNA.
The tested methods included:
- Silica column-based extraction systems
- Magnetic bead purification systems
- Phenol–chloroform extraction methods
- Guanidinium isothiocyanate (GIT)-based protocols
Researchers compared each method based on:
- Recovery of endogenous 18S ribosomal RNA
- Recovery of short synthetic RNA fragments
- Scalability for large plasma volumes
- Compatibility with downstream RT-PCR analysis
Superior Performance of Precipitation-Based Methods
The study demonstrated that precipitation-based extraction methods provided the highest RNA recovery.
The most effective approaches included:
- Modified GIT–phenol extraction
- TriBD reagent extraction
In contrast, silica-column and magnetic bead methods showed poor recovery of short RNA fragments. This finding was particularly important because circulating plasma RNA was found to be highly fragmented.
The modified phenol–chloroform extraction protocol provided the best overall performance for isolating fragmented extracellular RNA from plasma and serum samples.
Concentration of Plasma RNA
Filtration-Based RNA Concentration
Because plasma RNA concentrations are extremely low, researchers investigated methods to concentrate RNA from larger plasma volumes.
Spin Column Concentration
Spin columns with molecular-weight cutoffs were tested but failed to efficiently retain fragmented plasma RNA.
0.2 µm Filtration Strategy
A second approach used 0.2 µm filters to trap RNA-containing vesicles.
This strategy produced several important findings:
- Most circulating RNA was retained by the filter
- RNA recovery increased substantially after vesicle isolation
- Pretreatment with GIT before filtration prevented RNA retention, confirming that vesicle structures were responsible for trapping RNA
These results strongly supported the concept that circulating RNA exists within membrane-bound particles larger than 0.2 µm.
Real-Time RT-PCR Analysis
Molecular Detection Methods
The isolated RNA was analyzed using quantitative reverse transcription PCR (QRT-PCR).
Several cancer-associated transcripts were targeted:
Melanoma Markers
- Tyrosinase
- MART-1
Esophageal Cancer Markers
- Cytokeratin 19 (CK19)
- Cytokeratin 20 (CK20)
Additional housekeeping genes such as:
- 18S rRNA
- β-GUS
- β-actin
were used for RNA quantification and quality assessment.
Detection of Circulating Tumor-Related RNA
Melanoma RNA Detection
Researchers analyzed serum RNA from patients with advanced melanoma.
Despite using:
- Large serum volumes
- Optimized RNA extraction
- Sensitive QRT-PCR assays
- Multiplex amplification systems
no detectable tyrosinase or MART-1 transcripts were identified in patient serum samples.
Positive controls consistently produced amplification, confirming that assay sensitivity was technically adequate.
Esophageal Cancer RNA Detection
The study also evaluated CK19 and CK20 mRNA expression in plasma from esophageal cancer patients.
Initial single-round RT-PCR showed no reliable detection.
Seminested RT-PCR slightly improved sensitivity but still failed to consistently distinguish cancer patients from control individuals.
Several explanations were proposed:
- Extremely low RNA concentrations
- RNA fragmentation
- Biological variability
- Presence of epithelial RNA markers in noncancer inflammatory conditions such as GERD
Overall, circulating RNA markers lacked sufficient diagnostic specificity and reproducibility.
Mechanisms of Circulating RNA Protection
Evidence Supporting Vesicle Encapsulation
The experiments strongly suggested that extracellular RNA is protected within lipid-containing vesicles rather than through association with DNA.
Supporting observations included:
- Resistance to RNase degradation
- Sensitivity to detergent-mediated membrane disruption
- Retention by 0.2 µm filtration
- Failure of RNase-H treatment to degrade RNA
These findings are highly consistent with the biological behavior of:
- Exosomes
- Microvesicles
- Apoptotic bodies
Clinical Implications for Cancer Diagnostics
Advantages of RNA-Based Diagnostics
Circulating RNA offers several theoretical advantages over DNA-based cancer biomarkers:
Tissue Specificity
RNA transcripts can reflect tissue-specific gene expression, potentially helping identify tumor origin.
Higher Copy Number
Each cell contains many RNA transcripts compared with only two copies of genomic DNA.
Dynamic Gene Expression Information
RNA profiles may provide insight into tumor activity and biological behavior.
Major Limitations Identified
Despite these advantages, the study identified several important limitations:
- Low abundance of tumor-derived RNA
- Extensive RNA fragmentation
- Biological contamination from platelets and normal cells
- Difficulty distinguishing cancer-specific signals
- Limited sensitivity for early-stage disease detection
Even after extensive optimization, circulating RNA analysis failed to provide clinically reliable cancer detection.
Conclusion
This study provided important insights into the biology of circulating extracellular RNA and its potential role in cancer diagnostics.
The research demonstrated that:
- Circulating RNA exists in stable, amplifiable form in plasma and serum
- RNA stability is likely mediated by encapsulation within lipid vesicles or apoptotic bodies
- Precipitation-based extraction methods provide superior RNA recovery
- Plasma RNA can be concentrated using vesicle filtration approaches
- Tumor-related RNA detection remains technically challenging
Although extracellular RNA shows significant biological interest, the study concluded that circulating plasma RNA was not sufficiently sensitive or reliable for routine cancer diagnosis using the technologies available at the time.
Nevertheless, these findings laid important groundwork for future developments in:
- Liquid biopsy technologies
- Exosome research
- Circulating nucleic acid diagnostics
- Noninvasive cancer biomarker discovery
- Precision oncology applications